| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_113001f16b5885d43803e02dd4c831cd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate |
2022-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9874f757fd39ada672edefbebbe411d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2834f6f51748a38faf6e4a7c4958c944
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fb5155af7f89cc94a0d95cbbfa52d07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53f61230d7d9bd95c897d0e45bbee048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b172594d7beb17a5cf022290a5ef72f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae895b66a61064083a3e82032b23f0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ca7c5443ab1734a8a501e03fd99d739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9174744e71b31d684b9874fd278b1278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_638b2c8e587487939692f89c3176cb58 |
| publicationDate |
2022-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022186521-A1 |
| titleOfInvention |
Recombinant protein toxic to cd30-expressing cells, and pharmaceutical composition for treatment of cancer comprising same as active ingredient |
| abstract |
The present invention relates to a recombinant protein that is toxic to CD30-expressing cells and, specifically, to a recombinant protein comprising a CD30 ligand protein having a high affinity for CD30, and a pharmaceutical composition for the treatment of CD30-expressing cancer using same. An extracellular domain of CD30 of the recombinant protein of the present invention recognizes the CD30 ligand and binds to specific CD30-expressing cancer cells, and the human immunoglobulin G1 (human IgG1) heavy chain constant region of the recombinant protein binds to an IgG receptor (FcγRIIIa, CD16a) of a natural killer cell and transmits an activation signal to the inside of the natural killer cell, such that the recombinant protein can have cytotoxicity against CD30-expressing cancer and can be used by binding a drug conjugate thereto. Accordingly, the recombinant protein according to the present invention can be effectively used as a therapeutic agent having specific cytotoxicity to CD30-expressing carcinoma. |
| priorityDate |
2021-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |